PMID- 20121625
OWN - NLM
STAT- MEDLINE
DCOM- 20110309
LR  - 20181201
IS  - 1532-2513 (Electronic)
IS  - 0892-3973 (Linking)
VI  - 32
IP  - 4
DP  - 2010 Dec
TI  - Immunomodulatory effects of rosuvastatin on hepatic ischemia/reperfusion induced 
      injury.
PG  - 555-61
LID - 10.3109/08923970903575716 [doi]
AB  - Liver ischemia followed by reperfusion results in liver injury which in turn 
      produces and releases destructive proinflammatory cytokines into the circulation 
      causing subsequent damage to other organs. This remains a significant problem for 
      surgical procedures and liver transplantation. OBJECTIVE: In this study, we show 
      the effect of rosuvastatin on multiple organ dysfunction induced by 
      hepatic/ischemia reperfusion. MATERIALS AND METHODS: Hepatic ischemia and 
      reperfusion (I/R) injury was induced in rats, and groups of rats were pretreated 
      with oral rosuvastatin. RESULTS: Our study detected the levels of tumor necrosis 
      factor-alpha (TNF-alpha), interleukin 6 (IL-6), IL-10, and monocyte chemotactic protein 1 
      (MCP-1) not only in serum but also in liver, lung, kidney intestine, and heart 
      tissues. Rosuvastatin pretreatment appears to protect these organs after hepatic 
      I/R injury through the reduction of proinflammatory cytokines (TNF-alpha, IL-6, and 
      MCP-1) and stimulation of anti-inflammatory cytokines (IL-10) production. 
      DISCUSSION AND CONCLUSION: This is the first report of rosuvastatin 
      immunomodulatory effects on multiorgan dysfunction after hepatic I/R. Our data 
      suggest a therapeutic potential for rosuvastatin in attenuating inflammation and 
      modulating immune response independent of lipid lowering effect.
FAU - Awad, Azza S
AU  - Awad AS
AD  - Department of Pharmacology & toxicology, Faculty of Pharmacy, Al-Azhar 
      university, Nasr City, Cairo, Egypt.
FAU - El Sharif, Amany
AU  - El Sharif A
LA  - eng
PT  - Journal Article
DEP - 20100202
PL  - England
TA  - Immunopharmacol Immunotoxicol
JT  - Immunopharmacology and immunotoxicology
JID - 8800150
RN  - 0 (Ccl2 protein, rat)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Fluorobenzenes)
RN  - 0 (Immunologic Factors)
RN  - 0 (Interleukin-6)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 130068-27-8 (Interleukin-10)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
SB  - IM
MH  - Animals
MH  - Blood/drug effects/metabolism
MH  - Chemokine CCL2/blood/metabolism
MH  - Fluorobenzenes/*therapeutic use
MH  - Heart/drug effects
MH  - Immunologic Factors/*therapeutic use
MH  - Interleukin-10/blood/metabolism
MH  - Interleukin-6/blood/metabolism
MH  - Intestinal Mucosa/metabolism
MH  - Intestines/drug effects
MH  - Kidney/drug effects/metabolism
MH  - Liver/*blood supply/drug effects/*metabolism
MH  - Lung/drug effects/metabolism
MH  - Male
MH  - Multiple Organ Failure/blood/etiology/metabolism/prevention & control
MH  - Myocardium/metabolism
MH  - Pyrimidines/*therapeutic use
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reperfusion Injury/blood/complications/metabolism/*prevention & control
MH  - Rosuvastatin Calcium
MH  - Sulfonamides/*therapeutic use
MH  - Tumor Necrosis Factor-alpha/blood/metabolism
EDAT- 2010/02/04 06:00
MHDA- 2011/03/10 06:00
CRDT- 2010/02/04 06:00
PHST- 2010/02/04 06:00 [entrez]
PHST- 2010/02/04 06:00 [pubmed]
PHST- 2011/03/10 06:00 [medline]
AID - 10.3109/08923970903575716 [doi]
PST - ppublish
SO  - Immunopharmacol Immunotoxicol. 2010 Dec;32(4):555-61. doi: 
      10.3109/08923970903575716. Epub 2010 Feb 2.